AAAAAA

   
Results: 1-17 |
Results: 17
Imaging for staging bladder cancer: a clinical study of (111)indium-labelled anti-MUC1 mucin intravenous monoclonal antibody C595
Authors: Hughes, ODM Perkins, AC Frier, M Wastie, ML Denton, G Price, MR Denley, H Bishop, MC
Citation: Odm. Hughes et al., Imaging for staging bladder cancer: a clinical study of (111)indium-labelled anti-MUC1 mucin intravenous monoclonal antibody C595, BJU INT, 87(1), 2001, pp. 39-46
The use of scintigraphy to demonstrate the rapid esophageal transit of theoval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of water
Authors: Perkins, AC Wilson, CG Frier, M Blackshaw, PE Dansereau, RJ Vincent, RM Wenderoth, D Hathaway, S Li, ZQ Spiller, RC
Citation: Ac. Perkins et al., The use of scintigraphy to demonstrate the rapid esophageal transit of theoval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of water, INT J PHARM, 222(2), 2001, pp. 295-303
The effect of the nasal cycle on mucociliary clearance
Authors: Soane, RJ Carney, AS Jones, NS Frier, M Perkins, AC Davis, SS Illum, L
Citation: Rj. Soane et al., The effect of the nasal cycle on mucociliary clearance, CLIN OTOLAR, 26(1), 2001, pp. 9-15
Oesophageal transit, disintegration and gastric emptying of a film-coated risedronate placebo tablet in gastro-oesophageal reflux disease and normal control subjects
Authors: Perkins, AC Wilson, CG Frier, M Blackshaw, PE Juan, D Dansereau, RJ Hathaway, S Li, Z Long, P Spiller, RC
Citation: Ac. Perkins et al., Oesophageal transit, disintegration and gastric emptying of a film-coated risedronate placebo tablet in gastro-oesophageal reflux disease and normal control subjects, ALIM PHARM, 15(1), 2001, pp. 115-121
Oesophageal bandaging: a new opportunity for thermosetting polymers
Authors: Potts, AM Wilson, CG Stevens, HNE Dobrozsi, DJ Washington, N Frier, M Perkins, AC
Citation: Am. Potts et al., Oesophageal bandaging: a new opportunity for thermosetting polymers, STP PHARM S, 10(4), 2000, pp. 293-301
Targeting superficial bladder cancer by the intravesical administration ofcopper-67-labeled anti-MUC1 mucin monoclonal antibody C595
Authors: Hughes, ODM Bishop, MC Perkins, AC Wastie, ML Denton, G Price, MR Frier, M Denley, H Rutherford, R Schubiger, PA
Citation: Odm. Hughes et al., Targeting superficial bladder cancer by the intravesical administration ofcopper-67-labeled anti-MUC1 mucin monoclonal antibody C595, J CL ONCOL, 18(2), 2000, pp. 363-370
Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources
Authors: Abram, WP Buxton-Thomas, M Carty, HML Clarke, SEM Coakley, AJ Cunningham, D Ell, P Elliott, AT Frier, M Gordon, I Gibson, CJ Gillen, GJ Harding, LK Henk, JM Hesslewood, SR Kendall, GM Lewington, V McCready, VR Mather, SJ McKillop, JH Millar, A Mountford, P Nunan, T Palmer, M Pippard, M Prescott, MC Shields, RA Stather, JW Stocks, MA Thomas, WH Tindale, W Waller, DG Watkinson, JC
Citation: Wp. Abram et al., Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources, NUCL MED C, 21, 2000, pp. III
Nuclear medicine imaging and drug delivery
Authors: Perkins, A Frier, M
Citation: A. Perkins et M. Frier, Nuclear medicine imaging and drug delivery, NUCL MED C, 21(5), 2000, pp. 415-416
Nuclear medicine communications
Authors: Nunan, TO Coakley, AJ Elliott, AT McDougall, IR Carrio, I Frier, M
Citation: To. Nunan et al., Nuclear medicine communications, NUCL MED C, 21(12), 2000, pp. 1093-1093
An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinoma
Authors: Davies, Q Perkins, AC Roos, JC Molthoff, CFM Verheijen, RHM Frier, M Kenemans, P Broadhead, T Sopwith, M Symonds, EM
Citation: Q. Davies et al., An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinoma, BR J OBST G, 106(1), 1999, pp. 31-37
Dry powder dosing in liquid vehicles: ocular tolerance and scintigraphic evaluation of a perfluorocarbon suspension
Authors: Zhu, YP Wilson, CG Meadows, D Olejnik, O Frier, M Washington, N Musson, R
Citation: Yp. Zhu et al., Dry powder dosing in liquid vehicles: ocular tolerance and scintigraphic evaluation of a perfluorocarbon suspension, INT J PHARM, 191(2), 1999, pp. 79-85
Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulations
Authors: Perkins, AC Wilson, CG Frier, M Vincent, RM Blackshaw, PE Dansereau, RJ Juhlin, KD Bekker, PJ Spiller, RC
Citation: Ac. Perkins et al., Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulations, INT J PHARM, 186(2), 1999, pp. 169-175
Evaluation of the clearance characteristics of bioadhesive systems in humans
Authors: Soane, RJ Frier, M Perkins, AC Jones, NS Davis, SS Illum, L
Citation: Rj. Soane et al., Evaluation of the clearance characteristics of bioadhesive systems in humans, INT J PHARM, 178(1), 1999, pp. 55-65
Radiopharmaceuticals for sentinel node detection
Authors: Frier, M
Citation: M. Frier, Radiopharmaceuticals for sentinel node detection, NUCL MED C, 20(4), 1999, pp. 306-308
The use of dual-isotope imaging to compare the gastrointestinal transit offood and pancreatic enzyme pellets in cystic fibrosis patients (vol 19, pg761, 1998)
Authors: Hillel, PG Tindale, WB Taylor, CJ Frier, M Senior, S Ghosal, S
Citation: Pg. Hillel et al., The use of dual-isotope imaging to compare the gastrointestinal transit offood and pancreatic enzyme pellets in cystic fibrosis patients (vol 19, pg761, 1998), NUCL MED C, 20(3), 1999, pp. 297-297
Bad blood and biologicals: The need for new radiopharmaceutical source materials
Authors: Perkins, AC Frier, M
Citation: Ac. Perkins et M. Frier, Bad blood and biologicals: The need for new radiopharmaceutical source materials, NUCL MED C, 20(1), 1999, pp. 1-2
Gastric emptying and intestinal transit of pancreatic enzyme supplements in cystic fibrosis
Authors: Taylor, CJ Hillel, PG Ghosal, S Frier, M Senior, S Tindale, WB Read, N
Citation: Cj. Taylor et al., Gastric emptying and intestinal transit of pancreatic enzyme supplements in cystic fibrosis, ARCH DIS CH, 80(2), 1999, pp. 149-152
Risultati: 1-17 |